Organic Active Ingredients TRIZ Cases

Heterocyclic ERK inhibitors target the Ras-Raf-Mek-Erk pathway to treat cancers with B-Raf and K-Ras mutations while improving safety margins.

Adeno-associated virus vectors deliver microRNA modulators to treat progressive fibrosing interstitial lung disease, bypassing systemic toxicity.

Lipid nanoparticle carriers encapsulate microRNA molecules to regulate gene expressions involved in inflammation and immune response.

Rosoxacin inhibits migration and tumor-sphere formation of triple-negative breast cancer cells, reducing metastasis.

Justicia procumbens extracts activate transglutaminase to boost ceramide levels, resolving unknown efficacy gaps in skin roughness prevention.

Segmented self-tapering dosages of clonidine and naltrexone reduce withdrawal severity while minimizing transition complexity.

Formula I compounds inhibit serine hydroxymethyltransferase enzymes, blocking glycine production and reducing cancer cell survival.

A personalized co-therapy regimen synchronizes GLP1 agonist dosing with digital behavioral programs to manage patient weight loss.

Indole derivatives inhibit MKLP-2 ATPase activity, resolving side effects from non-selective microtubule inhibitors.

Modified heterocyclic cores in Formula I compounds enhance antitumor potency while minimizing toxicity across multiple cancer types.

Topical sirolimus treats cutaneous proliferative conditions by reducing systemic side effects.

A transdermal hydroalcoholic gel composition delivers testosterone to improve glycemic control in type-2 diabetes patients.

Covalent chitosan-integrin linkages resolve nucleic acid degradation and safety trade-offs for precise gene silencing.

Enzymatic hydrolysis of babassu mesocarp flour produces white, high-crystallinity gluco-oligosaccharide with 60-90% amylopectin content.

Heating fatty acids above 100°C enables direct amide formation with aqueous proline, eliminating hazardous acid chlorides and inorganic salt waste.

Hot-melt formulation of flurbiprofen with polyvinylcaprolactam graft copolymer enhances drug solubility and dissolution rate.

Topical oxymetazoline constricts blood flow to relieve nerve irritation, avoiding complications from surgery or injections.

Specific ocular compounds mitigate disease progression in anterior segment disorders by protecting retinal cells from oxidative stress-induced cell death.

Administering a CD20 antagonist depletes B cells to reduce radiographic joint damage, addressing imprecision in measuring disease progression.

Quinolinol compounds disrupt the Mdm2-MdmX protein interaction, activating the p53 pathway and overcoming resistance from MdmX overexpression.

Segmented pen injector with self-service dosing mechanism eliminates manual withdrawal errors while maintaining sterile reservoir integrity.

Deuterium-enriched sulfonamide derivatives act as potent 5-HT1A receptor agonists, reducing side effects while enhancing pharmacokinetic reliability.

Polymerizing dopamine on aligned magnetic particles fixes interparticle spacing, preventing transient disintegration when external fields are removed.

Fusing a reporter gene to the endogenous frataxin locus enables accurate assessment of native chromosomal context during high-throughput screening.

RNAi oligonucleotides inhibit ACC and DGAT2 expression, reducing liver steatosis and triglyceride levels in metabolic syndrome.

Dual-function heterocyclic compounds inhibit beta-lactamase activity to restore antibiotic efficacy against resistant bacterial strains.

MAB21L4 mimics and RET inhibitors address the lack of targeted therapy for early lesions by reducing tumor progression and metastasis.

Quantifying total cell-free DNA levels in blood samples to monitor biological tissue damage.

An isotonic bowel-cleansing composition combines anhydrous sulfates with prucalopride to maintain osmolality between 280 and 320 mOsm/L.

Protective peptide and polysaccharide coatings shield probiotics from stomach acidity, ensuring viable delivery to the intestinal tract.

Metal catalyzed coupling and deprotection steps synthesize ledipasvir, reducing toxicity while maintaining hepatitis C virus inhibition.

Identifying and inhibiting JunD targets like MYC blocks carcinogenesis while resolving the trade-off between growth suppression and mechanistic understanding.

Polymorph A of vidofludimus calcium salt enhances anti-inflammatory efficacy while meeting strict regulatory limits on residual solvent impurities.

A bilayered tablet combines immediate and slow-release layers to deliver aceclofenac effectively.

PD-L1 detection selects patients for combination therapy, overcoming chemotherapy resistance and CAR-T toxicity.

Compounds covalently modify unique cysteine residues in CDK7, 12, and 13, resolving structural similarity challenges that hinder selective kinase targeting.

Fusing Cas9 with an HSV-1 UL12 polypeptide recruits the MRN complex to DNA breaks, resolving the trade-off between repair efficiency and editing precision.

Biodegradable polymer matrices encapsulate therapeutic sub-particles to enable sustained agent release from embolic devices.

An antibody-drug conjugate uses moderate antigen-binding affinity to distribute camptothecin payloads throughout cancer tissue.

Combining PDE1 and NEP inhibitors addresses limited efficacy and side effects in hypertension treatment.

A dog diet composition combines reduced methionine levels with a specific cysteine ratio to support metabolic health.

TAZ compounds inhibit AXL receptor tyrosine kinase function through specific triazolo-pyridine and triazolo-pyrimidine core structures.

Modified nucleotides enhance binding affinity, overcoming the inability of small molecules to target intracellular Chop.

Monitoring clinical response allows dose adjustment of digoxin or lisinopril to counteract bioavailability changes caused by oral octreotide co-administration.

Replacing benzamide with nicotinamide reduces inhibition of cardiovascular kinases while maintaining anti-cancer activity against resistant mutations.

Novel small molecule inhibitors target prolyl hydroxylase domain proteins to stabilize hypoxia-inducible factor.

Peptide agents limit 14-3-3ε and VDAC1 interactions to restore natural testosterone levels without altering luteinizing hormone.

A biomolecule conjugate incorporates non-natural amino acids to attach cytotoxic payloads via cycloaddition reactions.

Propylene glycol and glycerol carriers ensure cannabinoid solubility without precipitation, preventing turbidity issues in the final formulation.

Pyrimidine core substituents optimize selectivity against Abl mutants while maintaining broad-spectrum therapeutic coverage.

Dinucleotide compounds link modified nucleosides to inhibit viral replication while reducing toxicity.

Lipid nanoparticles encapsulate modified RNA encoding VEGF-A polypeptides to enhance cellular uptake and therapeutic protein expression.

Composite lipid nanoparticles shield mRNA from plasma nucleases while enabling cellular uptake and endosomal escape.

Tricyclic heteroaryl compounds inhibit EGFR, FAK, and SYK kinases to overcome drug resistance in cancer and fibrosis treatments.

Segmented formulae optimize binding affinity to reduce cancer cell proliferation.

Composite scoring of amphiregulin and epiregulin positivity resolves spatial context loss in PCR detection, improving treatment prediction accuracy.

Formula I compounds inhibit CETP activity to raise HDL-C and lower LDL-C, addressing modest efficacy and adverse effects of existing therapies.

A sulfonylindole derivative acts as an acid pump antagonist to treat peptic ulcer and gastritis through selective proton pump inhibition.

Metopimazine targets peripheral dopamine receptors to enhance gastric emptying without crossing the blood-brain barrier, avoiding cardiac side effects.

Formula 1 compounds trigger serine phosphorylation and degradation of IRS1/2 proteins.

RNA interference targeting these synthase genes reduces sorgoleone accumulation to mitigate allelopathic effects.

Perfluorinated oxazin compounds modulate beta-secretase activity to reduce A-beta peptide formation.

Modified triazolopyridine derivatives target drug-resistant breast and prostate cancer cells to overcome persistent uncontrolled growth.

Selenium and zinc minerals mediate radiation interaction with skin tissue, resolving the contradiction between therapeutic efficacy and harmful surface burns.

A carrier composition comprising phosphate electron transfer agents and polar protic solvents facilitates transdermal transport of lipophilic biologically active compounds.

Oral administration of purified preen oil reduces chronic inflammation in animals while improving aquaculture survival rates through unique fatty acid profiles.

Genotype-guided SCAP inhibitor dosing treats increased lipid levels by adapting to individual genetic variants.

Novel imidazo[1,5-a]pyridines inhibit indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase enzymes.

Bis-amide compounds bind the Troponin C/I interface to boost sarcomere activity, avoiding poor tissue selectivity and adverse effects of current inotropes.

Pyrazole compounds inhibit monoacylglycerol lipase, addressing limited therapeutic options for pain and migraine by regulating endocannabinoid levels.

Combining HDAC6 selective inhibitors with BTK inhibitors targets chronic lymphocytic leukemia cells through synergistic apoptosis induction.

2-HOBA targets specific dicarbonyls without disrupting normal ROS signaling, resolving the high-dose antioxidant trade-off in atherosclerosis treatment.

Segmented triazinone scaffolds optimize inhibition potency and selectivity for PI4KIIIβ, resolving trade-offs between efficacy and toxicity.

Cyclohexyl pyridine derivatives resolve drug-drug interactions by reducing CYP3A4 inhibitory activity while maintaining antiemetic efficacy.

A composite tablet uses a nested core-shell structure to combine two active pharmaceutical ingredients into a single dosage form.

Structurally novel epoxysuccinic acid derivatives enhance inhibitory activity against Cathepsin B and L to treat tumors, osteoporosis, and viral infections.

A rice koji extract containing 9-HODE activates PPARα to promote fatty acid beta-oxidation.

Beta-glucan and maltodextrin in a powdered thickener improve cohesiveness and reduce aspiration risk while maintaining organoleptic properties.

Medium chain triglyceride vehicle disperses temozolomide via surfactants, increasing Cmax and AUC while reducing Tmax compared to solid formulations.

Novel substituted tetrahydropyran dihydrothienopyrimidines act as potent phosphodiesterase inhibitors.

Phosphonate analogues with high chiral purity treat viral infections while minimizing drug resistance and toxicity.

An ionizable lipid compound with optimized carbon chain length forms nanoparticles that penetrate cell membranes.

A segmented single-dose pill isolates distinct medications within one unit to prevent chemical interference between active ingredients.

Direct binding 8-hydroxyquinoline compounds inhibit GLI1 and SRC kinase, resolving modest in vivo activity of prior inhibitors.

Modified oligonucleotides target MAPT mRNA to reduce tau protein expression, addressing insufficient binding affinity and side-effects in current therapies.

Low molecular weight polymeric reagents with aliphatic lipid-thioester groups deliver nucleic acids to hematopoietic cells while reducing cellular toxicity.

Acetaminophen injection composition uses solubilizing agents to prevent recrystallization during distribution.

Covalent bonding of substituted quinazolines locks KRAS G12C mutants in inactive states, reducing cell proliferation.

L-NIL inhibits inducible nitric oxide synthase to regenerate damaged lung tissue.

A butorphanol patch uses a silicone adhesive layer to accelerate drug skin permeation.

Nucleoside-modified mRNA encapsulated in lipid nanoparticles enables intraspinal delivery of therapeutic proteins.

Crystallization inhibitors prevent tadalafil reagglomeration in oral films, maintaining solubility.

A high-concentration plant sterol capsule filling uses bile salts to achieve rapid gastric disintegration.

A self-administration auto-injector delivers risperidone microspheres suspended in a non-aqueous liquid vehicle.

Formula I compounds establish hydrophobic interactions with the MTHFD2 active site to inhibit enzyme activity.